Compare Quest Diagnostics Inc (DGX) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Moody's Corporation — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Moody's Corporation trades at $493.7 (market cap $86.42B). The key difference: Moody's Corporation is far larger — about 3.8× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | MCO | |
|---|---|---|
Market Cap | $22.80B | $86.42B |
Sector | Health | Financials |
52-Week High | $216.02 | $539.61 |
52-Week Low | $166.42 | $412.23 |
Enterprise Value | $28.82B | $92.22B |
Dividend Yield | 1.67% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MCO trades at $495.72, up 1.73% today, with strong technical momentum as price hovers near pivot point resistance at $496. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while recent AI platform expansions signal growth initiatives. Analyst consensus remains bullish with a $539.40 price target, though valuation multiples appear elevated.
Outlook remains positive given earnings momentum and strategic AI investments, but high P/E of 35.56 presents valuation risk. Key catalysts include Q2 2026 earnings release on July 22, while regulatory scrutiny and debt market sensitivity represent ongoing headwinds for the credit ratings leader.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
